

ALKEM LABORATORIES LTD

DATE- 2 August 2024



Leading Pharmaceutical company^[1] Alkem is the fifth largest player in domestic formulation market with a market share of 3.9% as on March 31, 2022. It has established its leadership position in acute therapy, with a strong market position in anti-infective, gastrointestinal, pain management, vitamins, minerals, and nutrient segments.

Product Portfolio : Branded Generics , Generic Drugs, API ,Nutraceuticals and Biosimilars.


OUR RECOMMENDATION:

OPTION INSIGHT: BUY ALKEM 5300 CALL BETWEEN 229-234 TARGETS 287-333 STOP LOSS BELOW 198

MARKET CAP	P/E	DIVIDEND YIELD	ROCE	ROE	FACE VALUE	3YEARS SALES GROWTH	3YEARS PROFIT GROWTH
RS.63,591 CR.	33.6	0.77 %	19.7 %	19.6 %	2.00	13%	7%



SHAREHOLDING PATTERN MARCH 24



■ PROMOTERS ■ FII ■ DII ■ PUBLIC



TECHNICAL ANALYSIS

Alkem is consolidating on daily charts. The stock recovered from its psychological level of 5200 and sustains above 5300 also. The stock has moved above Super Trend Indicator and 34 period EMA on 5 min chart. The stock broke the previous day's resistance of 5320. The stock has also formed an inverse head and shoulder pattern and stock was trading above the neckline of the pattern. We anticipate a quick breakout from these levels so Buy call was given in 5300 Call Option.

DISCLAIMER

I, **Ruchi Nahar**, SEBI Registered Research Analyst (**INH000014544**) comply with the qualification and certification requirements under SEBI (Research Analyst) Regulations, 2014. I have qualified **CA, CS and MBA**, has over 11 years of experience in MNCs, culminating as Head of Finance. I now leverages my expertise to guide stock market investors with strategic insights. All of the views expressed in research reports and recommendations issued by me reflect my personal views about the subject company or companies at the given point of time and I do not receive/accept any kind of compensation, directly or indirectly related to specific recommendations or views expressed in reports issued by me. I/my relatives do not at any point of time of issuing the reports have any material conflict of interest in the subject company neither I was/am/will be engaged in market making activity for the subject company. The investments discussed or views expressed in reports and recommendations issued by me may not be suitable for all investors. The user assumes the entire risk of any use made of this information. I nor any person connected with my report, accepts any liability arising from the use of research document. The recipients of research document should rely on their own investigations and should consult their own financial advisors to determine merit and risks of such investments based on their own risk appetite. Price and value of the investments referred to in this material may go up or down. Past performance is not a guide for future performance. Certain transactions including those involving futures, options and other derivatives as well as non-investment grade securities involve substantial risk and are not suitable for all investors. Reports and recommendations based on technical analysis centres on studying charts of a stock's price movement and trading volume, as opposed to focusing on a company's fundamentals and as such, may not match with a report on a company's fundamentals. Opinions expressed in research reports & recommendations will be based on the current opinions as of the date appearing in research report & recommendations. While I endeavour to update on a reasonable basis the information discussed in research reports, there may be regulatory, compliance, or other reasons that prevent me from doing so. Prospective investors and others are cautioned that any forward-looking statements are not predictions and may be subject to change without notice. So far as reports include current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed. Investment in securities market is subject to market risks. Read all the related documents carefully before investing. Registration granted by SEBI, and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

02.08.2024

